ArticleClinical and translational science2025

Evaluating the Impact of Hepatic or Renal Impairment on Tanimilast (CHF6001) Pharmacokinetics: Two Open-Label, Parallel-Group, Single-Center Studies.

Annalisa Piccinno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.